Clinical trials: Dermatitis, Atopic
Atopic Dermatitis
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis
- Trial name
- ALLEVIAD (NCT02525094)
- Testing
- MEDI9929
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 113 people
- Sponsor
- MedImmune LLC
Atopic Dermatitis
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the safety, tolerability, and efficacy of a multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
- Trial name
- NCT06055374
- Testing
- BxC-I17e
- Sponsor
- Brexogen Inc.
Atopic Dermatitis
Clinical Investigation on the Efficacy and Safety of Relizema Cream in Paedriatric Patients
The scope of this multicenter, double blind, randomized, vehicle-controlled clinical investigation is to evaluate and confirm the performance and safety of the Relizema cream in the improvement of the dermatitis severity in…
- Trial name
- YOUNG (NCT05259774)
- Testing
- Relizema cram
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Relife S.r.l.
Atopic Dermatitis
Bodewell Products for the Treatment of Atopic Dermatitis
This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products
- Trial name
- NCT05566262
- Testing
- Bodewell Calming Cream
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Alabama at Birmingham
Atopic Dermatitis
A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
To demonstrate the therapeutic equivalence and safety of Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) and OPZELURA (Ruxolitinib) Cream in the treatment of mild-to-moderate atopic dermatitis
- Trial name
- NCT06673654
- Testing
- Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream
- Where
- United States
- Volunteers
- 476 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Smallpox, Atopic Dermatitis
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
purpose of this study is to assess the safety and immunogenicity of two MVA smallpox vaccine injections in healthy adults that are 18-35 years of age with a history of mild to moderate Atopic Dermatitis.
- Trial name
- NCT00389103
- Testing
- MVA (smallpox vaccine)
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dermatitis, Atopic, Pruritus
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
Atopic dermatitis is a common disease affecting millions worldwide. A common associated symptom in this population is pruritus. We seek to investigate the use of an natural, over-the-counter cosmeceutical to help this population
- Trial name
- NCT06488742
- Testing
- 3% kanuka oil
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Nexgen Dermatologics, Inc.
Atopic Dermatitis
Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis
Atopic dermatitis (AD) is a common skin disease that has increased in prevalence worldwide two- to threefold over the last 50 years.
- Trial name
- NCT00460083
- Testing
- Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Ceragenix Pharmaceuticals
Atopic Dermatitis, Atopic Dermatitis (AD)
Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis
This randomized, open-label, parallel-group study will compare the efficacy and safety of Crisaborole 2% ointment and Tacrolimus 0.1% ointment in children with mild to moderate atopic dermatitis.
- Trial name
- NCT07162896
- Testing
- Crisaborole 2%, Tacrolimus 0.1%
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Shalamar Institute of Health Sciences
Atopic Dermatitis, Eczema
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
The utility of functionally relevant signature genes in assessing the clinical outcomes of dupilumab treatment in the adult onset atopic dermatitis
- Trial name
- NCT04358224
- Testing
- Dupilumab Prefilled Syringe
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonathan A. Bernstein, MD
Atopic Dermatitis, Psoriasis
Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis
Cathelicidins are small proteins in the human body that protect against infection. The purpose of this study is to determine if the amount of cathelicidins and other small proteins found in saliva can predict the amount of these…
- Trial name
- NCT00407979
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis
The objective of this study was to evaluate the safety and efficacy of multiple doses of upadacitinib monotherapy versus placebo in the treatment of adults with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT02925117
- Testing
- Upadacitinib
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- AbbVie
Atopic Dermatitis
The Therapeutic Effects of Topical Cannabidiol (CBD) Products for Atopic Dermatitis
The goal of this observational study is to learn about the potential therapeutic effects of topical CBD products produced by Phoilex Ltd., specifically the Releaf Gel, in those diagnosed with atopic dermatitis.
- Trial name
- NCT06022874
- Testing
- Phoilex Releaf Gel
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Phoilex Ltd.
Atopic Dermatitis
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
- Trial name
- NCT01228513
- Testing
- ZK245186
- Where
- 16 sites in United States, Japan
- Volunteers
- 263 people
- Sponsor
- Bayer
Dermatitis, Atopic
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986166 and of branebrutinib, each versus placebo, for the treatment of participants with moderate to severe atopic dermatitis.
- Trial name
- NCT05014438
- Testing
- BMS-986166, Branebrutinib
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 17 people
- Sponsor
- Bristol-Myers Squibb
Atopic Dermatitis
Effect of Holly Mangrove Shower Gel in Atopic Dermatitis Patients
Atopic dermatitis is a chronic intermittent inflammatory skin disease. Currently, there are many cosmeceutical skin products in which their major action affects skin hydration and skin barrier function.
- Trial name
- NCT02178215
- Testing
- Holly Mangrove Shower Gel
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Mahidol University
Atopic Dermatitis Eczema
Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 28 days vs vehicle application on treatment of mild to moderate AD
- Trial name
- NCT03235024
- Testing
- B244, Vehicle
- Where
- 17 sites in United States
- Volunteers
- 122 people
- Sponsor
- AOBiome LLC
Pruritus, Atopic Dermatitis
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
This is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with atopic dermatitis (AD) and moderate to…
- Trial name
- KARE (NCT04018027)
- Testing
- difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg
- Where
- 40 sites in United States, Canada
- Volunteers
- 401 people
- Sponsor
- Cara Therapeutics, Inc.
Atopic Dermatitis
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)
The purpose of phase I clinical trial is to evaluate safety and efficacy in subjects with over Moderately subacute and chronic Atopic Dermatitis after inject.
- Trial name
- NCT01927705
- Testing
- FURESTEM-AD Inj.
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis, Healthy Volunteers
A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants
The purpose of this study is to evaluate microneedle-based collection of dermal interstitial skin fluid (dISF) in healthy participants and atopic dermatitis (AD) participants
- Trial name
- NCT06934980
- Testing
- Microneedle Device
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation